If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-29. Numbers and descriptions here follow the published literature rather than marketing material.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Auf diese Weise konnte bewiesen werden, dass das Basentriplett UUU die Aminosäure Phenylalanin codiert. Mit der gleichen Methode konnte dem Basentriplett AAA und dem Triplett CCC die Aminosäuren Lysin und Prolin zugeordnet werden. Das Codon GGG konnte bei dem Experiment jedoch noch nicht entschlüsselt werden, aufgrund dessen Sekundärstruktur, die dazu führte, dass das Basentriplett nicht an die Ribosomen gebunden werden konnte. In einem weiteren Versuch wurde dem System eine mRNA mit der Basensequenz UCU hinzu gegeben. Radioaktives Serin fand sich nun auf dem Filter (d. h. Synthese von Poly-Serin), radioaktives Phenylalanin hingegen im Filtrat (d. h. keine Synthese von Poly-Phenylalanin). Aus diesen Ergebnissen konnte man schließen, dass bei Zusammenpassen von Basentriplett mit der Aminosäure eine Proteinbiosynthese stattfindet und die mRNA translatiert wird. Horace Freeland Judson wies auf einige glückliche Umstände des Experiments zum Beispiel in der Wahl von UUU hin. Es war handhabbarer und effizient als andere künstliche RNAs und das Produkt Phenylalanin sehr leicht nachzuweisen, es war so träge und unlöslich, dass es fast von selbst zum Niederschlag kam. Judson trat aber auch der Einschätzung eines Glückstreffers entgegen, zumal Nirenberg und Matthaei zum Zeitpunkt des Experiments als Wissenschaftler auf diesem Gebiet völlig unbekannt waren und ihr Durchbruch für etablierte Wissenschaftler in dem Gebiet völlig überraschend kam.
So wurde bekannt, dass nur eine wenig geringere Magnesium-Konzentration, wie sie etwa in der Zelle unter natürlichen Bedingungen herrschen, das Experiment mit UUU hätte scheitern lassen. Matthaei und Nirenberg hatten aber den Magnesium-Anteil systematisch variiert. Beide hatten bei der Konzeption des Experiments keinen direkten Kontakt zu den führenden Forschergruppen und gingen nach Angaben in der Literatur vor (Paul Zamecnik und M. R. Lamborg und insbesondere einem Labor-Report von Alfred Tissières).
== Literatur == Horace Freeland Judson: The eighth day of creation, Cold Springer Harbor Press 1996, S. 453ff Hans-Jörg Rheinberger: Experimentalsysteme – Eine Geschichte der Proteinsynthese im Reagenzglas. Wallstein Verlag, ISBN 3-89244-454-4.
Unter Polyamine werden meist gesättigte, offenkettige oder cyclische organische Verbindungen zusammengefasst, mit endständigen Aminogruppen, unterbrochen von einer wechselnden Anzahl sekundärer Aminogruppen. Polyamine sind je nach Kettenlänge farblos bis gelblich gefärbt und sind entweder flüssig oder fest. Die systematische Benennung nach der IUPAC-Nomenklatur wird mit Aza- vorgenommen.
Sources: de.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.